X-linked lymphoproliferative disease: Genetic lesions and clinical consequences

Current Allergy and Asthma Reports

Volumn 2, Issue 5, 2002, Pages 361-367

  MacGinnitie, Andrew J ^a   Geha, Raif ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Common Variable Immune Deficiency; Common Variable Immunodeficiency; Epstein Barr Virus; Epstein Barr Virus Infection; Hemophagocytic Lymphohistiocytosis

Indexed keywords

GENETIC LINKAGE; GENETICS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; REVIEW; X CHROMOSOME;

HUMANS; LINKAGE (GENETICS); LYMPHOPROLIFERATIVE DISORDERS; X CHROMOSOME;

EID: 0036718154     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-002-0068-0     Document Type: Article

References (49)

1. Purtilo DT, Cassel CK, Yang JP, Harper R: X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet 1975, 1:935–940. DOI: 10.1016/S0140-6736(75)92004-8
2. Seemayer TA, Gross TG, Egeler RM, et al.: X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995, 38:471–478. DOI: 10.1203/00006450-199510000-00001
3. Hamilton JK, Paquin LA, Sullivan JL, et al.: X-linked lymphoproliferative syndrome registry report. J Pediatr 1980, 96:669–673. DOI: 10.1016/S0022-3476(80)80735-9
4. Seemayer TA, Grierson H, Pirruccello SJ, et al.: X-linked lymphoproliferative disease. Am J Dis Child 1993, 147:1242–1245.
5. Morra M, Silander O, Calpe S, et al.: Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001, 98:1321–1325. Reports on six patients diagnosed with common variable immunodeficiency subsequently found to have mutations in the SAP gene. Four of six died of infection or complications of infections. DOI: 10.1182/blood.V98.5.1321
6. Nistala K, Gilmour KC, Cranston T, et al.: X-linked lymphoproliferative disease: three atypical cases. Clin Exp Immunol 2001, 126:126–130. Describes three patients diagnosed with common variable immunodeficiency with no SAP expression. The index patient went on to develop fatal fulminant infectious mononucleosis. DOI: 10.1046/j.1365-2249.2001.01599.x
7. Sumazaki R, Kanegane H, Osaki M, et al.: SH2D1A mutations in Japanese males with severe Epstein-Barr virus--associated illnesses. Blood 2001, 98:1268–1270. The authors studied 40 males with severe EBV-associated disease, and identified 10 who had SAP mutations. Nine had fulminant infectious mononucleosis and one an EBV-positive lymphoma. DOI: 10.1182/blood.V98.4.1268
8. Arico M, Imashuku S, Clementi R, et al.: Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001, 97:1131–1133. A study reporting that four of 25 patients with apparently sporadic hemophagocytic lymphohistiocytosis secondary to EBV had muations in SAP. DOI: 10.1182/blood.V97.4.1131
9. Liebowitz D: Epstein-Barr virus--an old dog with new tricks. N Engl J Med 1995, 332:55–57. DOI: 10.1056/NEJM199501053320112
10. Cohen JI: Epstein-Barr virus and the immune system. Hide and seek. JAMA 1997, 278:510–513. DOI: 10.1001/jama.278.6.510
11. Wrensch M, Weinberg A, Wiencke J, et al.: Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol 2001, 154:161–165. DOI: 10.1093/aje/154.2.161
12. Purtilo DT, Grierson HL, Davis JR, Okano M: The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975–1990. Pediatr Pathol 1991, 11:685–710.
13. Imashuku S: Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol 2000, 72:1–11.
14. Sumegi J, Huang D, Lanyi A, et al.: Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000, 96:3118–3125.
15. Harada S, Sakamoto K, Seeley JK, et al.: Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects. J Immunol 1982, 129:2532–2535.
16. Grierson HL, Skare J, Hawk J, et al.: Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am J Med Genet 1991, 40:294–297. DOI: 10.1002/ajmg.1320400309
17. Cunningham-Rundles C, Bodian C: Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92:34–48. DOI: 10.1006/clim.1999.4725
18. Harrington DS, Weisenburger DD, Purtilo DT: Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 1987, 59:1419–1429. DOI: 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P
19. Brandau O, Schuster V, Weiss M, et al.: Epstein-Barr virusnegative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999, 8:2407–2413. DOI: 10.1093/hmg/8.13.2407
20. Yin L, Toccco T, Pauly S, et al.: Absence of SH2D1A point mutations in 62 Burkitts lymphoma cell lines. Am J Hum Genet 1999, 65(Suppl):A331.
21. Mehta VK, Massad MG, Tripathi SP, et al.: Immune-deficient bronchiectasis associated with X-linked lymphoproliferative disease. Ann Thorac Surg 1999, 68:578–580. DOI: 10.1016/S0003-4975(99)00603-7
22. Dutz JP, Benoit L, Wang X, et al.: Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood 2001, 97:95–100. DOI: 10.1182/blood.V97.1.95
23. Loeffel S, Chang CH, Heyn R, et al.: Necrotizing lymphoid vasculitis in X-linked lymphoproliferative syndrome. Arch Pathol Lab Med 1985, 109:546–550.
24. Grossniklaus HE, Aaberg TM, Purnell EW, et al.: Retinal necrosis in X-linked lymphoproliferative disease. Ophthalmology 1994, 101:705–709.
25. Sakamoto K, Seeley JK, Lindsten T, et al.: Abnormal anti-Epstein Barr virus antibodies in carriers of the X-linked lymphoproliferative syndrome and in females at risk. J Immunol 1982, 128:904–907.
26. Henter JI, Arico M, Egeler RM, et al.: HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the Histiocyte Society. Med Pediatr Oncol 1997, 28:342–347. DOI: 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H
27. Filipovich AH, Blazar BR, Ramsay NK, et al.: Allogeneic bone marrow transplantation for X-linked lymphoproliferative syndrome. Transplantation 1986, 42:222–224.
28. Pracher E, Panzer-Grumayer ER, et al.: Successful bone marrow transplantation in a boy with X-linked lymphoproliferative syndrome and acute severe infectious mononucleosis. Bone Marrow Transplant 1994, 13:655–658.
29. Gross TG, Filipovich AH, Conley ME, et al.: Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant 1996, 17:741–744.
30. Myers LA, Patel DD, Puck JM, Buckley RH: Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002, 99:872–878. DOI: 10.1182/blood.V99.3.872
31. Vowels MR, Tang RL, Berdoukas V, et al.: Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med 1993, 329:1623–1625. DOI: 10.1056/NEJM199311253292205
32. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669–672. DOI: 10.1126/science.288.5466.669
33. Parolini S, Bottino C, Falco M, et al.: X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000, 192:337–346. DOI: 10.1084/jem.192.3.337
34. Bottino C, Falco M, Parolini S, et al.: NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001, 194:235–246. DOI: 10.1084/jem.194.3.235
35. Sullivan JL, Byron KS, Brewster FE, Purtilo DT: Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science 1980, 210:543–545. DOI: 10.1126/science.6158759
36. Argov S, Johnson DR, Collins M, et al.: Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. Cell Immunol 1986, 100:1–9. DOI: 10.1016/0008-8749(86)90001-8
37. Sayos J, Wu C, Morra M, et al.: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462–469. DOI: 10.1038/26683
38. Coffey AJ, Brooksbank RA, Brandau O, et al.: Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129–135. DOI: 10.1038/2424
39. Nichols KE, Harkin DP, Levitz S, et al.: Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998, 95:13765–13770. DOI: 10.1073/pnas.95.23.13765
40. Sayos J, Nguyen KB, Wu C, et al.: Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000, 12:1749–1757. DOI: 10.1093/intimm/12.12.1749
41. Poy F, Yaffe MB, Sayos J, et al.: Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 1999, 4:555–561. DOI: 10.1016/S1097-2765(00)80206-3
42. Morra M, Simarro-Grande M, Martin M, et al.: Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem 2001, 276:36809–36816. DOI: 10.1074/jbc.M101305200
43. Wu C, Nguyen KB, Pien GC, et al.: SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2001, 2:410–414. DOI: 10.1038/ni0901-823
44. Czar MJ, Kersh EN, Mijares LA, et al.: Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/ SAP. Proc Natl Acad Sci U S A 2001, 98:7449–7454. DOI: 10.1073/pnas.131193098
45. Morra M, Howie D, Grande MS, et al.: X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 2001, 19:657–682. DOI: 10.1146/annurev.immunol.19.1.657
46. Tangye SG, Lazetic S, Woollatt E, et al.: Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999, 162:6981–6985.
47. Benoit L, Wang X, Pabst HF, et al.: Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 2000, 165:3549–3553.
48. Latour S, Gish G, Helgason CD, et al.: Regulation of SLAMmediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001, 2:681–690. This study Identified a potentially new role for SAP in intracellular signaling. SAP can change the conformation of the intracellular portion of SLAM, allowing recruitment of the Fyn tyrosine kinase. DOI: 10.1038/90615
49. Sylla BS, Murphy K, Cahir-McFarland E, et al.: The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B. Proc Natl Acad Sci U S A 2000, 97:7470–7475. This report demonstrated an association of SAP with p62dok, and showed that SAP can activate NK-_B. This further expands the number of pathways in which SAP is apparently involved. DOI: 10.1073/pnas.130193097